Skip to main content
Bern researcher viewing sample)

Research & Development

Innovation is in Our DNA

Innovation is in our DNA and is the core of everything we do at CSL Behring. Our team of over 1,700 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.

  • US $922 million

    was invested in R&D in 2019/20 across our businesses

  • US $3.7 billion

    in R&D investments in the last 5 years advances product pipeline

  • >1,700

    research & development employees

Female Scientist at Broadmeadows

Investment in our R&D

Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area Condition Study
Number 
Description Status
(Click on link to learn more)
COVID-19 COVID-19 CSL312_COVID-19 A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) Recruiting
  COVID-19  CSL324_COVID-19 CSL324 in COVID-19 Not Yet Recruiting
Haematology and Thrombosis
Hemophilia A CSL627_3001 An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A Active, Not Recruiting
Hemophilia B CSL654_3003 A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Active, Not Recruiting
Reversal of acquired coagulation factor deficiency BE1116_4001 An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding Recruiting
  Sickle Cell CSL200_1001 CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Recruiting
  Sickle Cell CSL889_1001          A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease  Not Yet Recruiting 
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001 Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Recruiting
  Diabetic Kidney Disease            CSL346_2001 A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease             Recruiting           
Immunology and Neurology Dermatomyositis (DM) IgPro20_3007 A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) Recruiting
  Pediatric CIDP IgPro10_4002 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting
  Hereditary Angioedema (HAE) CSL312_2001 A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Active, Not Recruiting
  Hereditary Angioedema (HAE) CSL830_3003  A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects  Recruiting 
  Hidradenitis Suppurativa and Palmoplantar Pustulosis CSL324_1002 A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis Recruiting
  Systemic Sclerosis IgPro10_2001 Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis Active, Not Recruiting
  Systemic Sclerosis IgPro20_2001 A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  Healthy Subjects CSL324_1003 Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects Not Yet Recruiting
  Healthy Subjects CSL730_1001 Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults Cancelled
  Healthy Subjects CSL730_1002 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects  Recruiting
Respiratory Mild Asthma CSL311_1001 A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Active, Not Recruiting
  alpha-1 antitrypsin deficiency  AmAREtTI Study  Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)  Recruiting 
Transplant Antibody-mediated kidney transplant rejection CSL842_3001 Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Active, Not Recruiting
  Antibody-mediated kidney transplant rejection  CSL300_3001  A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients  Recruiting 
  Acute GVHD (aGVHD) CSL964_2001 The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) Recruiting
  Graft Versus Host Disease (GVHD) CSL964_5001 A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD Recruiting

 

COMPLETED STUDIES:

Haematology and Thrombosis Congenital Fibrinogen Deficiency  BI3023_4003  An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
  Von Willebrand Disease CSLCT-BIO-12-83 Study of Voncento® in Subjects With Von Willebrand Disease  Completed
Cardiovascular and Metabolic Coronary Heart Disease CSL112_1001 Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
Renal Impairment and Acute Myocardial Infarction  CSL112_2001 A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction Results
Immunology and Neurology Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004 Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro10_5004 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)  Completed
  HIV-1 CAL-USA-11 An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART Results
  Primary Immune Deficiency (PID) IgPro20_1001 Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump  Completed
  Primary Immune Deficiency (PID) IgPro20_4004 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Results
  Primary Immune Deficiency (PID) IgPro20_4005 Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Results
  Healthy Subjects CSL324_1001  Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
         

World-Class R&D Network

CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

CSL Parkville office

Australia

PARKVILLE, VIC
CSL Limited
Global Corporate HQ
R&D and Manufacturing

BROADMEADOWS, VIC
CSL Behring
R&D and Manufacturing

NORTH MELBOURNE, VIC
Bio21 Global Research and Translational Medicine Hub

Marburg employees

Germany

MARBURG
CSL Behring
R&D and Manufacturing

Kankakee office

United States

KING OF PRUSSIA, PA
CSL Behring
Head Office and R&D

KANKAKEE, IL
CSL Behring
R&D and Manufacturing

PASADENA, CA
Calimmune
R&D

Bern, Switzerland

Switzerland

BERN
CSL Behring
R&D and Manufacturing

Researchers taking notes

Japan

TOKYO
CSL Behring
R&D

Asian male and caucasian female in a lab

China

WUHAN
Ruide
R&D and Manufacturing

R&D Briefings Archives

R&D Briefing  October 2020  file 
R&D Briefing  December 2019  file 
R&D Briefing  December 2018  file 
R&D Briefing  December 2017  file
R&D Briefing December 2016 file
R&D Briefing December 2015 file
R&D Briefing December 2014 file
R&D Briefing December 2013 file